A Novel Cytotoxic T lymphocyte Epitope Analogue with Enhanced Activity Derived From Cyclooxygenase‐2
A Novel Cytotoxic T lymphocyte Epitope Analogue with Enhanced Activity Derived From Cyclooxygenase‐2
复制标题
DOI：
10.1111/j.1365-3083.2012.02738.x
复制
发表时间：
2012-09
影响因子：
3.7
通讯作者：
Yahong Wu;Yanfeng Gao;Y. J. He;Ranran Shi;Ming-xia Zhai;Zongyin Wu;Meng Sun;Wenjie Zhai;X. Chen;Yuanming Qi
中科院分区：
文献类型：
--
作者：
Yahong Wu;Yanfeng Gao;Y. J. He;Ranran Shi;Ming-xia Zhai;Zongyin Wu;Meng Sun;Wenjie Zhai;X. Chen;Yuanming Qi
环氧合酶- 2是一种很有前景的癌症免疫治疗靶点。在这里，我们设计了类似物p321‐9L和p321‐1Y9L （YLIGETIKL）从环加氧酶‐2衍生的天然肽p321。然后，我们测试了这些类似物的结合亲和力和稳定性，以及它们在体外（来自HLA‐A*02+健康供体的pbmc）和体内（来自HLA‐A2.1/Kb转基因小鼠）引发特异性免疫反应的能力。结果表明，p321‐9L和p321‐1Y9L诱导的细胞毒性T淋巴细胞活性比p321更强。综上所述，表位类似物，特别是p321‐1Y9L，可能是一个很好的候选物，可以用于表达环氧化酶‐2的肿瘤患者的免疫治疗。
Cyclooxygenase‐2 is a promising target for cancer immunotherapy. Here, we designed the analogues p321‐9L and p321‐1Y9L (YLIGETIKL) from cyclooxygenase‐2‐derived native peptide p321. Then, we tested the binding affinity and stability of the analogues and their ability to elicit specific immune response both in vitro (from PBMCs of HLA‐A*02+ healthy donors) and in vivo (from HLA‐A2.1/Kb transgenic mice). Our results indicated that the activity of cytotoxic T lymphocytes induced by p321‐9L and p321‐1Y9L was more potent than that of p321. In conclusion, the epitope analogue, especially p321‐1Y9L, may be a good candidate which could be used to the immunotherapy of patients with tumours expressing cyclooxygenase‐2.